Trial Profile

A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adegramotide/nelatimotide (Primary) ; Adegramotide/nelatimotide (Primary)
Indications Acute myeloid leukaemia; Glioblastoma; Malignant melanoma; Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma
Focus Adverse reactions
Sponsors Sumitomo Pharma America

Most Recent Events

03 May 2021 Results published in the Targeted Oncology
08 Nov 2019 According to a Boston Biomedical media release, data from the study will be presented a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting 2019.
08 Nov 2019 Results presented in a Boston Biomedical media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com